Johnson & Johnson Stock
Johnson & Johnson
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- CEO
- Joaquin Duato
- Employees
- 141,700
- Market cap
- $615.9 B
- IPO
- 02/01/1962
- Web
- www.jnj.com
Johnson & Johnson operates in the Healthcare / Drug Manufacturers - General sector as a leading U.S. company in the pharmaceutical and medical technology industries. Founded in 1887 and headquartered in New Brunswick, NJ, the holding company primarily divides its operations into the Innovative Medicine and MedTech…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Johnson & Johnson stock: price history
1D
+0.9%
1W
-2.2%
1M
-4.4%
6M
+9.1%
YTD
+23.5%
1Y
+33.0%
2Y
+55.6%
5Y
+58.4%
10Y
+121.4%
Next earnings date
Next earnings date
20/01/2027 (in 95 days)
Volatility around earnings
~21% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Johnson & Johnson stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Johnson & Johnson is a U.S.-based holding company in the healthcare sector operating in two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on the research, development, and distribution of pharmaceuticals in specialized areas such as immunology, oncology, and neuroscience. In the MedTech area, the company offers solutions for surgery, orthopedics, and ophthalmology. The business model is primarily based on the sale of pharmaceutical products and medical technologies across various geographic markets, with a significant portion of revenues generated in the United States.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Johnson & Johnson
Analyst assessment of Johnson & Johnson
PRICE TARGET LOW
US$260.00
CONSENSUS
US$284.33
MEDIAN
US$280.00
PRICE TARGET HIGH
US$320.00
0
STRONG BUY
21
BUY
16
HOLD
3
SELL
0
STRONG SELL
40
TOTAL · Buy
As of: 15/10/2026
Johnson & Johnson stock metrics
P/E
38.75
P/B
7.36
EV/EBITDA
20.92
RETURN ON EQUITY
0.0%
NET MARGIN
0.8%
DEBT/EQUITY
0
DIVIDEND YIELD
2.1%
AS OF
30/09/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
2,405,970,462
AVG. DAILY VOLUME (30D)
7,086,022
Insider transactions (SEC)
Schmid Timothy
Schmid Timothy
Schmid Timothy
Schmid Timothy
Taubert Jennifer L
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.9%
Search (Google Trends)
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Johnson & Johnson stock
What does Johnson & Johnson do?
Johnson & Johnson is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.
The CEO is Joaquin Duato, the company employs around 141,700 people.
The IPO was on 02/01/1962; the stock trades on NYSE under the ticker JNJ.
What do analysts say about Johnson & Johnson stock?
40 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$284.33, ranging from US$260.00 to US$320.00, with a median of US$280.00.
This is an external assessment, not a statement by Market Jury.
When does Johnson & Johnson report next?
The next earnings date is 20/01/2027.
Around past earnings, price swings were roughly 21% stronger than usual.
Does Johnson & Johnson pay a dividend?
Yes. The last dividend was US$1.34 per share, ex-date 24/11/2026, paid on 08/12/2026.
The dividend yield is 2.1% (as of 30/09/2026).
Which stocks are comparable to Johnson & Johnson?
Comparable stocks include Eli Lilly and Company, AbbVie, Merck &, Amgen, Gilead Sciences, Pfizer, Bristol-Myers Squibb Company and Biogen.
How can I get Johnson & Johnson stock analyzed?
Clicking "Analyze stock" lets five strategies assess Johnson & Johnson against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.